



Allocation of COVID-19 Monoclonal Antibodies and Other Novel Therapeutics

Michael Ganio, Pharm.D., M.S., FASHP


Senior Director, Pharmacy Practice and Quality

American Society of Health-System Pharmacists




Allocation Decisions

- Timely, transparent, equitable
- Fairness and consistency of data
- Clear communication to sites



Considerations for infusion sites

- Identifying patients
- Operational challenges
- Personnel





Identifying Patients – Meeting EUA Criteria

- Testing location and results vs. infusion location
 - Availability of drug supply
 - Communication and referral process
 - Rapid testing results and efficiency of scheduling and infusing




Identifying Patients – Criteria for Use




Operational Challenges

- COVID-19 positive outpatients
- Identifying and protecting healthcare personnel
- Dose preparation and safety



Operational Challenges

- COVID-19 positive outpatients
- Identifying and protecting healthcare personnel
- Dose preparation and safety



<https://dailymed.nlm.nih.gov/dailymed/index.cfm>



Allocation of COVID-19 Monoclonal Antibodies and Other Novel Therapeutics

Michael Ganio, Pharm.D., M.S., FASHP

Senior Director, Pharmacy Practice and Quality

American Society of Health-System Pharmacists

mganio@ashp.org

